Pediatrix Medical Group reported second-quarter 2026 adjusted earnings per share of 63 cents, beating the Zacks Consensus Estimate by 10.5% and up 18.9% year over year, while net revenues rose 4.1% to $487.8 million, surpassing estimates by 2.2%. The company's performance was driven by improved cash collections and a favorable payor mix, partly offset by lower patient volumes and higher operating costs. Management reaffirmed its 2026 adjusted EBITDA guidance of $280-$300 million and raised its net income forecast to $147.6-$162.1 million. Shares have gained 3.4% since the earnings report, outperforming the S&P 500, and estimates have trended upward, though the stock carries a Zacks Rank #3 (Hold).
Mednax IncQ2 EPS of 63 cents beat estimates by 10.5% and revenue rose 4.1% to $487.8M, with raised net income guidance
Danaher Corporation